Supplemental CNS Safety

Unique adverse effects may be suspected based on the pharmacological property or observations made during the drug characterization process. Additional concerns may arise during clinical trials. In such cases, follow-up studies are recommended (ICH S7A). We can provide the following supplemental services:

1. Tests for dependence and abuse liability;
2. Tests for cognitive liability; and
3. Tests for pro-convulsant liability.